BiotechTube

Pimavanserin + Placebo

Phase 2/3Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Irritability Associated With Autism Spectrum Disorder

Conditions

Irritability Associated With Autism Spectrum Disorder

Trial Timeline

Aug 9, 2022 → Sep 27, 2024

NCT ID
NCT05523895

About Pimavanserin + Placebo

Pimavanserin + Placebo is a phase 2/3 stage product being developed by Acadia Pharmaceuticals for Irritability Associated With Autism Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT05523895. Target conditions include Irritability Associated With Autism Spectrum Disorder.

What happened to similar drugs?

1 of 5 similar drugs in Irritability Associated With Autism Spectrum Disorder were approved

Approved (1) Terminated (0) Active (4)
🔄KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
🔄KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
✅Aripiprazole + PlaceboBristol Myers SquibbApproved
🔄Brexpiprazole + PlaceboLundbeckPhase 3
🔄BrexpiprazoleLundbeckPhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT05523895Phase 2/3Completed
NCT04531982Phase 3Completed
NCT03968159Phase 3Completed
NCT03575052Phase 3Completed
NCT02970305Phase 2Completed
NCT02970292Phase 3Completed

Competing Products

7 competing products in Irritability Associated With Autism Spectrum Disorder

See all competitors
ProductCompanyStageHype Score
KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
47
KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
47
Aripiprazole + PlaceboBristol Myers SquibbApproved
43
Brexpiprazole + PlaceboLundbeckPhase 3
37
BrexpiprazoleLundbeckPhase 3
37
JZP541Jazz PharmaceuticalsPhase 2
24
PimavanserinAcadia PharmaceuticalsPhase 2/3
27